Original scientific paper
THE SIGNIFICANCE OF INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR-ALPHA LEVELS IN COGNITIVE IMPAIRMENT AMONG FIRST-EVER ACUTE ISCHAEMIC STROKE PATIENTS
Nataša Loga-Andrijić
orcid.org/0000-0002-1196-8880
; Department of Neurology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Novica T. Petrović
; Department of Neuropsychiatry, Faculty of Medicine, Foča, University of East Sarajevo,Foča,Bosnia and Herzegovina
Snežana Filipović-Danić
; Neurology Clinic, Faculty of Medicine, University of Pristina in Kosovska Mitrovica, Kosovska Mitrovica, Serbia
Snežana Marjanović
; Department of Neuropsychiatry, Faculty of Medicine, Foča, University of East Sarajevo,Foča,Bosnia and Herzegovina
Vekoslav Mitrović
; Department of Neuropsychiatry, Faculty of Medicine, Foča, University of East Sarajevo,Foča,Bosnia and Herzegovina
Svjetlana Loga-Zec
; Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Abstract
Background: Acute ischemic stroke (AIS) frequently results in the development of cognitive impairment, which quite often
persists. The pathophysiological mechanisms involved in the development of cognitive impairment are only partially elucidated. The
aim of this study was to evaluate the correlation between interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-) serum levels
with cognitive impairment in AIS patients.
Subjects and methods: This hospital-based case-control study was performed during December 2014 May 2018. A total
number of 130 randomly selected patients were prospectively recruited from the Department of Neurology, Clinical Center
University of Sarajevo. The study examined 100 first-ever AIS patients, while 30 comprised the non-stroke control group of patients
with discogenic lumbosacral radiculopathy. All participants were evaluated using the Mini-Mental State Examination, the Montreal
Cognitive Assessment, the Frontal Assessment Battery, and the Addenbrooke's Cognitive Examination-Revised. Cognitive testing and
laboratory analyses were performed within the first three days of admission in all patients while AIS patients were reassessed on the
15th day of hospitalization.
Results: Female stroke patients with cognitive impairment had significantly higher baseline levels of IL-6 (p<0.017), and TNF-
(p<0.017) than those without cognitive impairment. In the control measurement, a significant difference in IL-6 levels (p=0.037) in
male and TNF-=0.042) in female stroke patients with cognitive impairment was observed.
Conclusions: These findings indicate that pro-inflammatory cytokines are probably implicated in the pathogenesis of cognitive
decline in AIS patients.
Keywords
cognitive impairment; cytokines; inflammation; ischemic stroke
Hrčak ID:
266972
URI
Publication date:
4.10.2021.
Visits: 631 *